Another consideration is the whole exome sequencing that takes about 4 weeks per patient.
The P2b/3 study and the recent OLE studies, Excellence etc. all require a before and after sequencing. The before samples can be processed while the trial progress and the few Mb of data from each all likely available at the end of the trial.
The sampling, just blood, from the end of the studies and sequencing of it will take some time depending on the capacity in the sequencing lab(s) used by Anavex.
The other blood based biomarker tests should be taking place in parallel and do not take long.
It is obviously critical that the sequencing data is then correctly linked to each patient's other data for the analysis to be valid. About 450 samples from the end of P2b/3 study perhaps could to take a few months to receive, organise for KEM, run the analysis and understand the results. Altogether, not unreasonable to expect this taking a year+.
News 
Market Data 
Discover 
